Clinical Trial Update: The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating factors influencing 12-week efficacy of polyethylene glycol losenatide in type 2 diabetes patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• polyethylene glycol losenatide (polyethylene glycol losenatide)

Snippet

Sponsor: Nanjing First Hospital, Nanjing Medical University | Conditions: Type2 Diabetes Mellitus | Phase 4 | Status: UNKNOWN